<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PYRIDOSTIGMINE BROMIDE- pyridostigmine bromideÂ tablet, extended releaseÂ </strong><br>ALVOGEN INC.<br></p></div>
<h1><span class="Bold">Pyridostigmine Bromide Extended release Tablets, 180 mg<br>Rx Only</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<h1></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ac0549e3-167f-a22a-9a43-94dfff6ecd26"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Pyridostigmine bromide is an orally active <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor. Chemically, pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. Its chemical formula is C<span class="Sub">9</span>H<span class="Sub">13</span>BrN<span class="Sub">2</span>O<span class="Sub">2</span>, molecular weight 261.12. Its structural formula is: </p>
<p></p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=93454159-0c58-1980-34b9-4038a2260420&amp;name=structure.jpg">Â </p>
<p></p>
<p>Pyridostigmine Bromide Extended release Tablets contain 180 mg pyridostigmine bromide. Inactive Ingredients: carnuba wax, zein, calcium phosphate, colloidal silicon dioxide, and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_7dea232c-2a71-8c60-691a-48eca7d8eff2"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">ACTIONS
</span></h1>
<p class="First">Pyridostigmine Bromide Extended release Tablets inhibits the destruction of acetylcholine by <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine, but differs from it in certain clinically significant respects; for example, pyridostigmine is characterized by a longer duration of action and fewer gastrointestinal side effects.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_d48b9ccf-87ca-999a-b69c-fe5b578703e5"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATION </span></h1>
<p class="First">Pyridostigmine Bromide Extended release Tablets is useful in the treatment of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_d7be7abb-946c-3a0f-743f-e0dd5fa94ce7"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First">Pyridostigmine Bromide Extended release Tablets is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Care should be observed in the use of atropine for counteracting side effects, as discussed below.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="_3e312b45-a5a4-e15e-9cfd-0592f9d44120"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS
</span></h1>
<p class="First">Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. As is true of all cholinergic drugs, overdosage of Pyridostigmine Bromide Extended release Tablets may result in <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>, a state characterized by increasing <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> which, through involvement of the muscles of respiration, may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by extreme <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, and thus may be difficult to distinguish from <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> on a symptomatic basis. Such differentiation is extremely important, since increases in doses of Pyridostigmine Bromide Extended release Tablets or other drugs of this class in the presence of <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> or of a refractory or "insensitive" state could have grave consequences. Osserman and Genkins<span class="Sup">1</span> indicate that the differential diagnosis of the two types of crisis may require the use of edrophonium chloride as well as clinical judgment. The treatment of the two conditions obviously differs radically. Whereas the presence of myasthenic crisis suggests the need for more intensive anticholinesterase therapy, the diagnosis of <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>, according to Osserman and Genkins,<span class="Sup">1</span> calls for the prompt <span class="Italics">withdrawal </span>of all drugs of this type. The immediate use of atropine in <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> is also recommended. Atropine may also be used to abolish or obtund gastrointestinal side effects or other muscarinic reactions; but such use, by masking signs of overdosage, can lead to inadvertent induction of <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>.</p>
<p>For detailed information on the management of patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, the physician is referred to one of the excellent reviews such as those by Osserman and Genkins,<span class="Sup">2</span> Grob<span class="Sup">3</span> or Schwab.<span class="Sup">4,5</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_4b46fa8a-a47c-aab8-77d4-3e1b867e4404"></a><a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">Usage in </span><span class="Bold">Pregnancy </span>
</h2>
<p class="First">The safety of Pyridostigmine Bromide Extended release Tablets during pregnancy or lactation in humans has not been established. Therefore, use of Pyridostigmine Bromide Extended release Tablets in women who may become pregnant requires weighing the drug's potential benefits against its possible hazards to mother and child.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="_83ca64e1-409f-560a-e439-f5d3da2976e5"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTION </span></h1>
<p class="First">Pyridostigmine is mainly excreted unchanged by the kidney.<span class="Sup">6,7,8</span> Therefore, lower doses may be required in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, and treatment should be based on titration of drug dosage to effect.<span class="Sup">6,7</span></p>
<div class="Section" data-sectionCode="34081-0">
<a name="_717a95a1-c276-ae70-ec11-91ec39675115"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">Pediatric Use
</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="_ea7906bb-3bb3-a1fb-0971-1badda349c45"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First">The side effects of Pyridostigmine Bromide Extended release Tablets are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, increased peristalsis, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="4010476" conceptname="Excessive bronchial secretion">increased bronchial secretions</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>. Nicotinic side effects are comprised chiefly of <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculation</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_54cedec3-d0d6-f61b-ddea-2dc9f6424f0e"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">Each Pyridostigmine Bromide Extended release Tablet contains 180 mg pyridostigmine bromide. This form provides uniformly slow release, hence prolonged duration of drug action; it facilitates control of myasthenic symptoms with fewer individual doses daily. The immediate effect of a 180 mg Pyridostigmine Bromide Extended release Tablet is about equal to that of a 60 mg pyridostigmine bromide tablet; however, its duration of effectiveness, although varying in individual patients, averages 2Â½ times that of a 60 mg dose.</p>
<p><span class="Bold">Dosage <br></span>The size and frequency of the dosage must be adjusted to the needs of the individual patient. One to three Pyridostigmine Bromide Extended release Tablets, 180 mg, once or twice daily, will usually be sufficient to control symptoms; however, the needs of certain individuals may vary markedly from this average. The interval between doses should be at least 6 hours. For optimum control, it may be necessary to use the more rapidly acting tablets or syrup in conjunction with Pyridostigmine Bromide Extended release Tablets therapy.</p>
<p><span class="Italics">Note:</span> For information on a diagnostic test for <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, and for the evaluation and stabilization of therapy, please see product literature on edrophonium chloride.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="_6eb4ae2c-5a27-1cd4-4161-1a6986fd86c1"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Pyridostigmine Bromide Extended release Tablets, 180 mg, are supplied in bottles of 30 tablets, NDC 47781-335-30.</p>
<p>Pyridostigmine Bromide Extended release Tablets are available as a cream to yellow, capsule-shaped tablet, containing 180 mg pyridostigmine bromide, debossed â€œ335â€? on one side and has functional scoring on the other side.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="_ad4740cf-9428-6848-77e0-57d176ae29c8"></a><a name="section-9.1"></a><p></p>
<h2><span class="Bold">Storage  </span></h2>
<p class="First">Store Pyridostigmine Bromide Extended release Tablets at 25Â°C (77Â°F); excursions permitted to 15Â°C-30Â°C (59Â°F-86Â°F) [see USP Controlled Room Temperature]. Keep Pyridostigmine Bromide Extended release Tablets in a dry place with the silica gel (desiccant) enclosed.</p>
<p><span class="Italics">Note:</span> Because of the hygroscopic nature of the Pyridostigmine Bromide Extended release Tablets, mottling may occur. This does not affect their efficacy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="_d281a7d9-939f-b8e7-7e3e-54f16b63f39b"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">REFERENCES
</span></h1>
<p class="First">1 Osserman KE, Genkins G. Studies in <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>: Reduction in mortality rate after crisis. <span class="Italics">JAMA</span>. Jan 1963; 183:97-101.</p>
<p>2 Osserman KE, Genkins G. Studies in <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. <span class="Italics">NY State J Med</span>. June 1961; 61:2076-2085.</p>
<p>3 Grob D. <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia gravis</span>. A review of patho-genesis and treatment. <span class="Italics">Arch Intern Med</span>. Oct 1961; 108:615-638.</p>
<p>4 Schwab RS. Management of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. <span class="Italics">New Eng J Med</span>. Mar 1963; 268:596-597.</p>
<p>5 Schwab RS. Management of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. <span class="Italics">New Eng J Med</span>. Mar 1963; 268:717-719.</p>
<p>6 Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. <span class="Italics">Clin Pharmacol Ther</span>. 1980; 28:No. 1, 78-81.</p>
<p>7 Miller RD. Pharmacodynamics and pharmacokinetics of anticholinesterase. In: Ruegheimer E, Zindler M, ed. <span class="Italics">Anaesthesiology</span>. (Hamburg, Germany: Congress; Sep 14-21, 1980; 222-223.) (Int Congr. No. 538), Amsterdam, Netherlands: Excerpta Medica; 1981.</p>
<p>8 Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F. Pyridostigmine kinetics in healthy subjects and patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. <span class="Italics">Clin Pharmacol Ther</span>. 1985;5:495-501.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_49b091f2-2f5f-5542-e466-03406ad6da72"></a><a name="section-11"></a><p></p>
<h1></h1>
<p class="First"></p>
<p>Made in USA</p>
<p>Distributed by:<br>Alvogen, Inc.<br>Pine Brook NJ 07058 USA</p>
<p>PI335-00<br>Rev. 08/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_05741185-aa3d-96f1-82c0-9d88e8ede6a3"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">NDC</span> 47781-<span class="Bold">33</span><span class="Bold">5</span>-30</p>
<p><span class="Bold">Pyridostigmine<br>Bromide</span><br><span class="Bold">EXTENDED-RELEASE</span><br><span class="Bold">TABLETS</span></p>
<p><span class="Bold">Pharmacist: </span>Dispense in the unit of use container.</p>
<p><span class="Bold">180 mg</span></p>
<p><span class="Bold">CAUTION: EXTREMELY</span><br><span class="Bold">MOISTURE SENSITIVE.<br>DO NOT REMOVE<br>DESICCANT. CLOSE TIGHTLY.</span></p>
<p><span class="Bold">Rx only<br>30 Tablets</span></p>
<p><span class="Bold">Alvogen<span class="Sup">Â®</span></span><span class="Bold"></span><span class="Bold"><br></span></p>
<p><img alt="pyridostigmine-cover-label " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=93454159-0c58-1980-34b9-4038a2260420&amp;name=Pyridostigmine-cover-label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PYRIDOSTIGMINE BROMIDEÂ 		
					</strong><br><span class="contentTableReg">pyridostigmine bromide tablet, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:47781-335</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PYRIDOSTIGMINE BROMIDE</strong> (PYRIDOSTIGMINE) </td>
<td class="formItem">PYRIDOSTIGMINE BROMIDE</td>
<td class="formItem">180Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ZEIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">335</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:47781-335-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA204737</td>
<td class="formItem">06/29/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>ALVOGEN INC.
							(008057330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Norwich Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">132218731</td>
<td class="formItem">analysis(47781-335), manufacture(47781-335), pack(47781-335)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>809df75c-e42a-2fd6-182c-03f8defe21dc</div>
<div>Set id: 93454159-0c58-1980-34b9-4038a2260420</div>
<div>Version: 4</div>
<div>Effective Time: 20120925</div>
</div>
</div>Â <div class="DistributorName">ALVOGEN INC.</div></p>
</body></html>
